{"DataElement":{"publicId":"3235131","version":"1","preferredName":"Person Clinical Study Agent Hypersensitivity Exclusion Criteria Ind-2","preferredDefinition":"the yes/no indicator related to a person's hypersensitivity or allergy to study agent that prevents a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","longName":"3235130v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3235130","version":"1","preferredName":"Person Clinical Study Agent Hypersensitivity Exclusion Criteria","preferredDefinition":"information related to a person's hypersensitivity or allergy to study agent that prevents a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","longName":"2236731v1.0:3235128v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3235128","version":"1","preferredName":"Clinical Study Agent Hypersensitivity Exclusion Criteria","preferredDefinition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research. :An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):An exaggerated response by the immune system to a drug or other substance.:Exclusion; the act of restricting entrance or barring from participation.","longName":"C15206:C1708:C3114 :C25370","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hypersensitivity","conceptCode":"Hypersensitivity","definition":"An exaggerated response by the immune system to a drug or other substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Exclusion Criteria","conceptCode":"C25370","definition":"Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A329325E-C898-54AD-E040-BB89AD437E96","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-13","modifiedBy":"ONEDATA","dateModified":"2011-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A329325E-C8A9-54AD-E040-BB89AD437E96","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-13","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"},{"publicId":"3303197","version":"1","longName":"Phase 1/Pilot Consortium","context":"COG"}]},{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104941","version":"1","longName":"GOG-0281","context":"NRG"},{"publicId":"10000705","version":"1","longName":"GOG-0281","context":"NRG"},{"publicId":"4104900","version":"1","longName":"GOG-0277","context":"NRG"},{"publicId":"4104892","version":"1","longName":"GOG-0229O","context":"NRG"}]},{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280724","version":"1","longName":"Eligibility Checklist","context":"ABTC"}]},{"publicId":"5999742","version":"1","longName":"CRF CDEs","context":"CITN","ClassificationSchemeItems":[{"publicId":"5999747","version":"1","longName":"Eligibility CDEs","context":"CITN"}]}],"AlternateNames":[{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"3235130v1.0:2018257v1.0","type":"USED_BY","context":"CTEP"},{"name":"AgyHysenCHGIND","type":"COG GDE Short Name","context":"CTEP"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"3235130v1.0:2018257v1.0","type":"USED_BY","context":"NRG"},{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"3235130v1.0:2018257v1.0","type":"USED_BY","context":"CITN"},{"name":"HYPERSENSITIVITY_IND","type":"Context Short Name","context":"NRG"},{"name":"ABTC","type":"USED_BY","context":"ABTC"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"CCTG","type":"USED_BY","context":"CCTG"},{"name":"STAGT_HSNTY_IND","type":"OID, CCTG","context":"CCTG"},{"name":"3235130v1.0:2018257v1.0","type":"USED_BY","context":"CCTG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"IE_IEORRES_HYPERSENS","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"CRF Text2","type":"Alternate Question Text","description":"Has the subject had a prior reaction or have an inability to tolerate any of the dental products being used (such as severe topical or hypersensitivity reaction)","url":null,"context":"NIDCR"},{"name":"History of allergy or hyperse","type":"Preferred Question Text","description":"History of allergy or hypersensitivity to agents chemically similar to AFP464","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Does the patient have a history of severe hypersensitivity reaction to Taxotere (docetaxel) or other drugs formulated with polysorbate 80?","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_1","type":"Alternate Question Text","description":"Does the patient have a history of allergic reaction to Cephalosporin","url":null,"context":"CTEP"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Does the patient have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug, or excipients, or to dimethyl sulfoxide (DMSO), or to Cremophor EL (polyoxyethylated castor oil)?","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Does the patient have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, GSK2141795 or dimethyl sulfoxide (DMSO)?","url":null,"context":"CTEP"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Is patient allergic or hypersensitive to CHG?","url":null,"context":"CTEP"},{"name":"CRF Text 6","type":"Alternate Question Text","description":"History of allergic reactions attributed to compounds of similar chemical or biological composition to INCB024360, MELITAC 12.1, or other vaccine components","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_13","type":"Alternate Question Text","description":"Does the patient have known hypersensitivity to indicated agent","url":null,"context":"CTEP"},{"name":"NRG_CRF Text","type":"Alternate Question Text","description":"Does the patient have a known sensitivity reactions to products containing Cremaphor EL?","url":null,"context":"NRG"},{"name":"NRG_CRF Text 2","type":"Alternate Question Text","description":"Does the patient have allergic reactions attributed to compounds of similar chemical or biologic composition to EGEN-001 or other agents used in this study?","url":null,"context":"NRG"},{"name":"COG_CRF_TEXT_12","type":"Alternate Question Text","description":"Does the patient have a history of allergic reaction to a cephalosporin","url":null,"context":"CTEP"},{"name":"CRF Text 7","type":"Alternate Question Text","description":"History of allergic reactions attributed to compounds of similar chemical or biologic composition to CDX-1401 or CDX-301 or poly-ICLC","url":null,"context":"CTEP"},{"name":"NRG_CRF Text 3","type":"Alternate Question Text","description":"Does the patient have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to Trametinib, or excipients, or to dimethyl sulfoxide (DMSO), or to Cremophor EL (polyoxyethylated castor oil)?","url":null,"context":"NRG"},{"name":"CRF Text 8","type":"Alternate Question Text","description":"Has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475","url":null,"context":"CTEP"},{"name":"NRG_CRF text 14","type":"Alternate Question Text","description":"If yes, does the patient have known hypersensitivity to anthracenedione or other anthracyclines?","url":null,"context":"NRG"},{"name":"EAI141","type":"Alternate Question Text","description":"Does the participant have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F- fluorothymidine?","url":null,"context":"ECOG-ACRIN"},{"name":"EAI142 Text","type":"Alternate Question Text","description":"History of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FES?","url":null,"context":"ECOG-ACRIN"},{"name":"ABTC Question","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biological composition to Anti-LAG-3, Anti-CD137, and Anti-PD1?","url":null,"context":"ABTC"},{"name":"CRF_Text 9","type":"Alternate Question Text","description":"Does the patient have known hypersensitivity to pembrolizumab or any of its excipients","url":null,"context":"NRG"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Does patient have history of hypersensitivity to conductive hydrogel?","url":null,"context":"PBTC"},{"name":"COG_CRF_Text_14","type":"Alternate Question Text","description":"Does patient have a history of allergic reaction to medications that have a benzamide structure","url":null,"context":"COG"},{"name":"NRG_CRF_Text 16","type":"Alternate Question Text","description":"Does the patient have prior allergic reaction or hypersensitivity to study agents","url":null,"context":"NRG"},{"name":"NRG CRF_Text 15","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232?","url":null,"context":"NRG"},{"name":"PBTC_Text2","type":"Alternate Question Text","description":"Does the patient have a history of allergy or hypersensitivity to agents chemically similar to Ribociclib or its excipients ?","url":null,"context":"PBTC"},{"name":"COG_CRF_TEXT_15","type":"Alternate Question Text","description":"Does patient have hypersensitivity to indicated agents?","url":null,"context":"COG"},{"name":"CITN-1","type":"Alternate Question Text","description":"Patient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab) or Interferon-gamma.  Patients who are hypersensitive to E. Coli are also excluded.","url":null,"context":"CITN"},{"name":"CE7","type":"Alternate Question Text","description":"Does the patient have a history of a prior allergic reaction to memantine?","url":null,"context":"CCTG"},{"name":"PBTC_Text3","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition?","url":null,"context":"PBTC"},{"name":"CRF Text 9","type":"Alternate Question Text","description":"Does the patient have a history of severe hypersensitivity reaction to any monoclonal antibody?","url":null,"context":"CTEP"},{"name":"NRG_CRF_Text 17","type":"Alternate Question Text","description":"Does the patient have a known hypersensitivity to any of the study drugs or any of the study drug excipients?","url":null,"context":"NRG"},{"name":"NRG_TEXT 18","type":"Alternate Question Text","description":"Does the patient have a history of severe (grade 3-4) hypersensitivity reaction to any monoclonal antibody including nivolumab and/or any of its excipients?","url":null,"context":"NRG"},{"name":"NRG_CRF_TEXT19","type":"Alternate Question Text","description":"Does the patient have a contraindication to memantine, such as allergy or prior reaction, intractable seizures, current use of NMDA agonist, or alcohol or drug abuse which can exacerbate lethargy or dizziness with memantine?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Does the patient have a history of a severe hypersensitivity reaction to monoclonal antibody or pembrolizumab (MK-3475) and/or its excipients; and/or a severe hypersensitivity reaction to paclitaxel and/or carboplatin?","url":null,"context":"NRG"},{"name":"CRF Text10","type":"Alternate Question Text","description":"Does the patient have a history of hypersensitivity to olanzapine or megestrol acetate?","url":null,"context":"Alliance"},{"name":"CCTG_01","type":"Alternate Question Text","description":"Patient has history of allergic reactions attributed to compounds of similar chemical or biologic composition of study agents?","url":null,"context":"CCTG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Does patient have hypersensitivity to letermovir or any component of the formulation?","url":null,"context":"COG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Does the patient have prior allergic reaction or hypersensitivity to cetuximab, xevinapant, or any of its excipients?","url":null,"context":"NRG"}],"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A3293BAD-5DD8-6118-E040-BB89AD4338F9","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-13","modifiedBy":"TSESU","dateModified":"2023-07-05","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"2023.4.4 AQT added per ticket request CADSR0002268. ak","unresolvedIssues":null,"deletedIndicator":"No"}}